Supplementary Figure S3 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer

This is a Quantitative Study study.

Key Points

Findings show that ZNF384 may function as a tumor suppressor in prostate cancer, which provides a novel target for therapy.
The analysis highlights an enhancer variant associated with ferroptosis, indicating a link to precision therapy in cancer treatment.
Using multicohort studies and integrated omics data, researchers uncovered significant genetic links relevant to cancer progression.
The potential role of ferroptosis in precision therapy underscores the need for targeted treatment approaches to enhance patient outcomes.

We only have this paper's title and publication details.

Integrated omics analyses reveal ZNF384 as a tumor suppressor in prostate cancer, suggesting new therapeutic targets.

ZNF384 acts as a potential tumor suppressor gene in prostate cancer

No takes yet. Share an insight, caveat, or question.

Ma et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share